title: First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.
abstract: OBJECTIVE
  To evaluate a novel modality utilising ultrasound for renal denervation designed to reduce the duration of the intervention as well as to increase the consistency of the clinical outcome.
  
  
  RESULTS
  Eleven consecutive patients suffering from resistant hypertension as defined by the ESH-ESC guidelines were treated by transcatheter renal denervation using the CE-marked PARADISE™ technology (ReCor Medical, Ronkonkoma, NY, USA). An average of 5.1 ultrasound emissions were delivered in each subject for a total denervation duration of less than four minutes and the treatment was well tolerated by all patients. Both office and home blood pressure measurements showed an immediate, significant and sustained decrease in blood pressure. Three-month results were comparable to published data on radiofrequency renal denervation with an average reduction in office and home blood pressure of -36/-17 mmHg and -22/-12 mmHg, respectively.
  
  
  CONCLUSIONS
  Ultrasound renal denervation appears to be a safe and effective treatment for resistant hypertension and further studies will be performed to confirm these preliminary results.
authors.affiliation: Mediclinic Vergelegen, Somerset West, South Africa. tmabin@mweb.co.za
authors.forename: Tom
authors.initials: T
authors.lastname: Mabin
authors.forename: Marc
authors.initials: M
authors.lastname: Sapoval
authors.forename: Vincent
authors.initials: V
authors.lastname: Cabane
authors.forename: Joanne
authors.initials: J
authors.lastname: Stemmett
authors.forename: Mano
authors.initials: M
authors.lastname: Iyer
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000959:Antihypertensive Agents / Q000627:therapeutic use; D017763:Autonomic Denervation / Q000009:adverse effects / Q000379:methods*; D001794:Blood Pressure / Q000187:drug effects; D004351:Drug Resistance; D057510:Endovascular Procedures / Q000009:adverse effects; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D006973:Hypertension / Q000503:physiopathology / Q000628:therapy*; D007668:Kidney / Q000098:blood supply / Q000294:innervation*; D008297:Male; D008875:Middle Aged; D013019:South Africa; D013997:Time Factors; D016896:Treatment Outcome; D014464:Ultrasonic Therapy / Q000009:adverse effects
chemical_list: D000959:Antihypertensive Agents